From HIV to COVID-19, Molecular mechanisms of pathogens' trade-off and persistence in the community, potential targets for new drug development.
Antoine Fakhry AbdelMassihAbrar SedkyAhmed ShalabyAlAmira-Fawzia ShalabyAlia YasserAya MohyeldinBasma AminBasma SaleheenDina OsmanElaria SamuelEmmy AbdelfatahEveen AlbustamiFarida ElGhamryHabiba KhaledHana AmrHanya GaberIsmail MakhloufJanna AbdeldayemJana Waleed El-BeialyKarim MiladLaila El SharkawiLina AbosennaMadonna G SafiMariam AbdelKareemMarwa GaberMirna ElkadyMohamed IhabNora AbdelRaoufRawan KhaledReem ShalataRudayna MahgoubSarah JamalSeif El-Din El HawaryShady ElRashidySherouk El ShorbagyTony GergesYara KassemYasmeen MagdyYasmin OmarYasmine ShokryAya KamelRafeef HozaienNadine El-HusseinyMeryam El ShershabyPublished in: Bulletin of the National Research Centre (2022)
Recognizing the mutations that attenuate the most morbid characters of pathogens such as virulence or persistence can help in tailoring new therapies for such pathogens. Targeting macrophage tropism of HIV by carbohydrate-binding agents, or targeting the TMPRSS2 receptors to prevent pulmonary infiltrates of COVID-19 is an example of how important is to recognize such genetic mechanisms.
Keyphrases
- antimicrobial resistance
- coronavirus disease
- antiretroviral therapy
- gram negative
- hiv positive
- sars cov
- hiv testing
- hiv infected
- human immunodeficiency virus
- hepatitis c virus
- hiv aids
- men who have sex with men
- cancer therapy
- escherichia coli
- multidrug resistant
- mental health
- pseudomonas aeruginosa
- staphylococcus aureus
- pulmonary hypertension
- genome wide
- adipose tissue
- south africa
- gene expression
- copy number
- biofilm formation
- drug delivery
- transcription factor
- cystic fibrosis
- dna methylation
- risk assessment
- human health
- climate change